Primary Clinical Response of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma (r/r FL) in China

被引：0
|
作者：
Song, Yuqin [1 ]
Ying, Zhitao [1 ]
Yang, Haiyan [2 ]
Guo, Ye [3 ]
Li, Wenyu [4 ]
Zou, Dehui [5 ,6 ,7 ]
Wu, Jianqiu [8 ]
Yang, Su [9 ]
Zhang, Pian [9 ]
Ma, Meilin [9 ]
Zhou, Zisong [9 ]
Zheng, Hongxia [9 ]
Zhu, Jun [1 ]
机构：
[1] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China
[2] Chinese Acad Sci, Inst Canc & Basic Med IBMC, Dept Med Oncol, Hangzhou, Peoples R China
[3] Shanghai Dongfang Hosp, Tongji Univ, Dept Med Oncol, Shanghai, Peoples R China
[4] Guangdong Acad Sci, Dept Lymphoma, Guangdong Provincial Peoples Hosp, Guangzhou, Guangdong, Peoples R China
[5] Clin Res Ctr Blood Dis, State Key Lab Expt Hematol, Blood Dis Hosp, Tianjin, Peoples R China
[6] Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China
[7] Peking Union Med Coll, Tianjin, Peoples R China
[8] Affiliated Hosp Nanjing Med Univ, Jiangsu Inst Canc Res, Jiangsu Canc Hosp, Dept Med Oncol,Jiangsu Red Cross Canc Ctr, Nanjing, Peoples R China
[9] JW Therapeut Shanghai Co Ltd, Shanghai, Peoples R China
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-150085
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2434
引用
收藏
页数：4
相关论文
共 50 条
  • [11] Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL)
    Schuster, Stephen J.
    Dickinson, Michael
    Dreyling, Martin
    Martinez-Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio C.
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter
    Zia, Aiesha
    Morisse, Mony Chenda
    Fowler, Nathan Hale
    Thieblemont, Catherine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S403 - S404
  • [12] Primary analysis of the Phase 2 ELM-2 study: Odronextamab in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL)
    Chong, Geoffrey
    Taszner, Michal
    Novelli, Silvana
    Cho, Seok-Goo
    Villasboas, Jose C.
    Ubieto, Ana Jimenez
    Tessoulin, Benoit
    Poon, Michelle
    Tucker, David
    Walewski, Jan
    Song, Yuqin
    Bachy, Emmanuel
    Guidez, Stephanie
    Alonso, Aranzazu
    Jagadeesh, Deepa
    Luminari, Stefano
    Mayer, Laura Magnano
    Iskierka-Jazdzewska, Elzbieta
    Tani, Monica
    Cai, Jingxian
    Uppala, Amulya
    Shariff, Saleem
    Brouwer-Visser, Jurriaan
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth
    Kim, Tae Min
    CANCER RESEARCH, 2024, 84 (07)
  • [13] ECONOMIC EVALUATIONS IN RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): CHALLENGES FOR HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSIONS
    Forbes, C.
    Pustulka, I
    Zuchinali, P.
    Kumar, J.
    VALUE IN HEALTH, 2023, 26 (12) : S334 - S334
  • [14] CURRENT EPCORITAMAB PLUS RITUXIMAB AND LENALIDOMIDE (R2) PERCEPTIONS FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
    Levine, E.
    Gentile, D.
    Swain, R.
    Bone, R. N.
    Jennings-Zhang, L.
    Jeune-Smith, Y.
    Feinberg, B.
    VALUE IN HEALTH, 2024, 27 (12) : S342 - S342
  • [15] Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching-Adjusted Indirect Analysis
    Gao, Fenghua
    Sun, Cong
    Liu, Jing
    Yu, Jingwei
    He, Jin
    Meng, Xiangrui
    Liu, Xia
    Han, Xue
    Li, Lanfang
    Qiu, Lihua
    Qian, Zhengzi
    Zhou, Shiyong
    Xia, Zhen
    Yang, Su
    Zhou, Zisong
    Tian, Alex
    Qin, Yun
    Wang, Xianhuo
    Zhang, Huilai
    HEMATOLOGICAL ONCOLOGY, 2025, 43 (02)
  • [16] Glofitamab As Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients (pts) with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
    Morschhauser, Franck
    Carlo-Stella, Carmelo
    Dickinson, Michael
    Phillips, Tycel
    Houot, Roch
    Offner, Fritz
    Haioun, Corinne
    Corradini, Paolo
    Hutchings, Martin
    Sureda, Anna
    Martinez-Lopez, Joaquin
    Wrobel, Tomasz
    Wu, Shang-Ju
    Lundberg, Linda
    Mulvihill, Estefania
    Perez-Callejo, David
    Relf, James
    Panchal, Anesh
    Humphrey, Kathryn
    Bachy, Emmanuel
    BLOOD, 2021, 138
  • [17] EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL
    Vose, Julie
    Vitolo, Umberto
    Lugtenburg, Pieternella
    Chamuleau, Martine E. D.
    Linton, Kim M.
    Thieblemont, Catherine
    Sonnevi, Kristina
    Jurczak, Wojciech
    Olszewski, Adam J.
    Awan, Farrukh Tauseef
    Okada, Craig Y.
    Feldman, Tatyana A.
    Hutchings, Martin
    Favaro, Elena
    Hoehn, Daniela
    Li, Zhu
    Conlon, Rebekah
    Sancho, Juan-Manuel
    Chavez, Julio C.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [18] Relmacabtagene Autoleucel CD19 CART Therapy for Adults with Heavily-Pretreated Relapsed/Refractory Large B-Cell Lymphoma in China
    Song, Yuqin
    Ying, Zhitao
    Yang, Haiyan
    Guo, Ye
    Li, Wenyu
    Zou, Dehui
    Zhou, Daobin
    Wang, Zhao
    Zhang, Mingzhi
    Wu, Jianqiu
    Liu, Hui
    Zhang, Pian
    Yang, Su
    Zhou, Zisong
    Zheng, Hongxia
    Zhu, Jun
    BLOOD, 2021, 138
  • [19] TRANSCEND FL: phase 2 study results of lisocabtagene maraleucel (liso-cel) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL)
    Borchmann, Peter
    Morschhauser, Franck
    Dahiya, Saurabh
    Palomba, M. Lia
    Garcia-Sancho, Alejandro Martin
    Reguera Ortega, Juan Luis
    Kuruvilla, John
    Jaeger, Ulrich
    Cartron, Guillaume
    Izutsu, Koji
    Dreyling, Martin
    Kahl, Brad
    Ghesquieres, Herve
    Ardeshna, Kirit
    Goto, Hideki
    Barbui, Anna Maria
    Abramson, Jeremy S.
    Fleury, Isabelle
    Mielke, Stephan
    Farazi, Thalia
    Fasan, Omotayo
    Lymp, James
    Vedal, Min
    Nishii, Rina
    Avilion, Ariel
    Papuga, Jessica
    Nastoupil, Loretta J.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 142 - 143
  • [20] ELARA Trial Update: Long-Term Clinical Outcomes and Correlative Efficacy Analyses of Tisagenlecleucel in Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL)
    Fowler, Nathan
    Dreyling, Martin
    Dickinson, Michael
    Martinez-Lopez, Joaquin
    Kolstad, Arne
    Butler, Jason
    Ghosh, Monalisa
    Popplewell, Leslie
    Chavez, Julio
    Bachy, Emmanuel
    Kato, Koji
    Harigae, Hideo
    Kersten, Marie Jose
    Andreadis, Charalambos
    Riedell, Peter
    Ho, P. Joy
    Antonio Perez-Simon, Jose
    Chen, Andy
    Nastoupil, Loretta
    von Tresckow, Bastian
    Ferreri, Andres Jose Maria
    Teshima, Takanori
    Patten, Piers
    McGuirk, Joseph
    Petzer, Andreas
    Offner, Fritz
    Viardot, Andreas
    Zinzani, Pier
    Malladi, Ram
    Paule, Ines
    Zia, Aiesha
    Awasthi, Rakesh
    Han, Xia
    Germano, Davide
    O'Donovan, Darragh
    Ramos, Roberto
    Masood, Aisha
    Thieblemont, Catherine
    Schuster, Stephen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S534 - S535
12345